-
Mashup Score: 7MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma - PubMed - 8 hour(s) ago
In newly diagnosed multiple myeloma (NDMM), measurable residual disease (MRD) status is prognostically important, but its role in treatment-decisions remains unclear. In a phase II trial (NCT04113018), we assessed daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction followed …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants reacted to data from the MonumenTAL-1 trial in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
During a Case-Based Roundtable® event, @OmarNadeemMD and participants reacted to data from the MonumenTAL-1 trial. #mmsm https://t.co/0HIIRP3Yt7
-
-
Mashup Score: 7
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off. #mmsm | @RahulBanerjeeMD @DrKrinaPatel @TiffanyRic48662 @Rfonsi1 @sridevirajeeve @DrOlaLandgren https://t.co/Bh2gl9mj35
-
-
Mashup Score: 8
During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Saad Z. Usmani, MD, FACP, MBA, (@szusmani) discussed quality of life and the future with CAR T-cell therapies in multiple myeloma and beyond. #mmsm | @MSKCancerCenter https://t.co/gl4OLx3Puc
-
-
Mashup Score: 8
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In an interview with Targeted Oncology, Cesar Rodriguez, MD, (@myelomatips) discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma. #mmsm https://t.co/pMvRecmMFp https://t.co/E45PFKzsd8
-
-
Mashup Score: 2
During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma. #mmsm | @TulaneMedicine https://t.co/T4XwfSRmGd
-
-
Mashup Score: 0
Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Experts in multiple myeloma discussed real-world efficacy and safety data associated with the use of GPRC5D-targeting bispecific agents to treat patients with R/R multiple myeloma. #mmsm https://t.co/dtHiSv0Pze
-
-
Mashup Score: 0
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The first patient has been dosed with QXL138AM in a phase 1 trial for the treatment of locally advanced unresectable and/or metastatic solid tumors and multiple myeloma. #mmsm https://t.co/DjbnrljnYH
-
-
Mashup Score: 87
Key Points. Retreatment with previously refractory drugs is a viable option for late line relapsed/refractory multiple myeloma.Patients with a longer gap b
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet-
With my apologies to toddler parents everywhere… “Don’t lose it, reuse it!” Excellent @BloodAdvances work by Goel @MayoMyeloma @VincentRK @myelomaMD et al. Re-using old myeloma #MMsm drugs can work, esp if years out. Very relevant to post-CAR-T! https://t.co/YFjLFZrdGI https://t.co/HmpFU5KiUw
-
-
Mashup Score: 9
Bone Marrow Transplantation – Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on…
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet-
Now in @BMTjournal: outcomes with salvage collection and ASCT in #MMsm patients with poor mob the first time. I love this, albeit not for reason authors emphasized - maybe "salvage mobilization" to collect more stem cells before CAR-T if ⬆️ ICAHT risk? https://t.co/gAuHH2j0Oq https://t.co/e7cdI25Y6w
-
A big shoutout to @LevineCancer #mmsm crew for bringing this study to fruition. @manisha_bhutani @PlasmaCellPete @AtrashShebli @BarryAdamP 😊🙏🏽👏🏽👏🏽👏🏽👏🏽 https://t.co/cr8r0dUDre